Gilead to trial version of remdesivir that can be inhaled, as company targets two million courses by year-end

  • 📰 globeandmail
  • ⏱ Reading Time:
  • 8 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 92%

Business News News

Business Business Latest News,Business Business Headlines

Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial

. But producing and supplying billions of doses remain major concerns as the fast-spreading respiratory illness overwhelms health care systems around the world.“We will continue to collaborate globally to ensure sufficient worldwide supply,” Gilead chief executive officer Daniel O’Day said in aTwo major Indian drugmakers – Hetero Labs and Cipla Ltd – on Sunday gained approval to begin selling their generic versions of remdesivir in the country.

Gilead said an inhaled formulation of the drug would be given through a nebulizer, which could potentially allow for easier use outside hospitals.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Flunked its ebola vaccine trials, teetering with investors, till raised from the dead...drug touted by Trump.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 5. in BUSİNESS

Business Business Latest News, Business Business Headlines